Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Cancer Research|September 5, 2025
PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in RhabdomyosarcomaKatrina I Paras, Julia S Brunner, Angela M Montero, et al.
Science Advances|February 27, 2026
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcomaJosephine K Dermawan, Fabio Vanoli, Henry Traux de Wardi, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination TherapyJeremy Worley, Heeju Noh, Daoqi You, et al.
Pediatric Blood & Cancer|August 29, 2025
New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor CommitteeJessica D Daley, Susan L Whiteway, Christine M Heske, et al.
Cold Spring Harbor Molecular Case Studies|December 16, 2018
A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcomaDaniel Diolaiti, Filemon S Dela Cruz, Gunes Gundem, et al.
Genome Medicine|November 2, 2016
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinomaFilemon S Dela Cruz, Daniel Diolaiti, Andrew T Turk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma TrialsDamon R Reed, Asmin Tulpule, Jonathan Metts, et al.
Med (New York, N.Y.)|October 4, 2022
Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumorsDiego F Coutinho, Prabhjot S Mundi, Lianna J Marks, et al.
Pharmacology & Therapeutics|November 7, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancersMalcolm A Smith, Peter J Houghton, Richard B Lock, et al.
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
Pageof 5